Methotrexate: CIRTified for preventing atherosclerotic events?

08:00 EDT 1st June 2019 | BioPortfolio

Summary of "Methotrexate: CIRTified for preventing atherosclerotic events?"

No Summary Available


Journal Details

This article was published in the following journal.

Name: The journal of the Royal College of Physicians of Edinburgh
ISSN: 2042-8189
Pages: 136-138


DeepDyve research library

PubMed Articles [5681 Associated PubMed Articles listed on BioPortfolio]

Atherosclerotic Vascular Events in Systemic Lupus Erythematosus - an Evolving Story.

Atherosclerotic vascular events (AVEs) are a major cause of mortality and morbidity in systemic lupus erythematosus (SLE). We aimed to determine the impact of early recognition and therapy for both cl...

Fetal methotrexate syndrome: A systematic review of case reports.

Methotrexate is a folic acid antagonist known to be teratogenic in humans. Several cases of congenital malformations after fetal exposure to methotrexate have been published, resulting in the establis...

Circulating CD14CD16 classical monocytes do not associate with a vulnerable plaque phenotype, and do not predict secondary events in severe atherosclerotic patients.

Mouse studies have established distinct monocyte subtypes that participate in the process of atherosclerotic lesion formation. The pro-inflammatory Ly6C monocyte subtype actively contributes to murine...

Methotrexate for Prevention of Cardiovascular Events.

Methotrexate for Prevention of Cardiovascular Events.

Clinical Trials [5342 Associated Clinical Trials listed on BioPortfolio]

Study of Methotrexate in Lupus Erythematosus

The treatment of systemic lupus erythematosus (SLE) has been aimed at decreasing mortality and morbidity because the etiology of the disease is unknown. The general aim of this multicentre...

Prevention of Methotrexate Induced Nephrotoxicity and Prolonged Drug Elimination Time With 12 Hours Prehydration

Infusions with high-dose methotrexate 5 g/m2 or 8 g/m2 are used to treat children with acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma, medulloblastoma and ependymoma. Methotrex...

Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation

RATIONALE: Sirolimus, tacrolimus, and methotrexate may be effective in preventing acute graft-versus-host disease in patients who are undergoing donor stem cell transplantation. PURPOSE: ...

Orientation of the Lymphocyte Response to the Occurrence of Atherosclerotic Complications After Kidney Transplantation

The incidence of atherosclerotic complications is increased after kidney transplantation. Traditional risk factors do not fully explain this increased risk. Atherosclerosis is an inflammat...

Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422AM1)(COMPLETED)

This study is undertaken to compare the efficacy and onset of action of infliximab plus methotrexate (IFX + MTX) versus methotrexate alone (MTX) in methotrexate naïve active psoriatic art...

Medical and Biotech [MESH] Definitions

Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.

A series of progressive, overlapping events, triggered by exposure of the PLATELETS to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug.

Narrowing or stricture of any part of the CAROTID ARTERIES, most often due to atherosclerotic plaque formation. Ulcerations may form in atherosclerotic plaques and induce THROMBUS formation. Platelet or cholesterol emboli may arise from stenotic carotid lesions and induce a TRANSIENT ISCHEMIC ATTACK; CEREBROVASCULAR ACCIDENT; or temporary blindness (AMAUROSIS FUGAX). (From Adams et al., Principles of Neurology, 6th ed, pp822-3)

The ongoing, systematic collection, analysis, and interpretation of health-related data with the purpose of preventing or controlling disease or injury, or of identifying unusual events of public health importance, followed by the dissemination and use of information for public health action. (From Am J Prev Med 2011;41(6):636)

Persons who experienced traumatic events during childhood.

Quick Search


DeepDyve research library

Searches Linking to this Article